Table 4.
Postoperative pain, recovery profiles and postoperative adverse effects
| Group A (n = 41) | Group B (n = 44) | Group C (n = 42) | P value | |
|---|---|---|---|---|
| Postoperative 0–2 h |
|
|
|
|
| Pain (VRS) |
36 (0–80) |
41 (0–90) |
39 (0–100) |
0.974 |
| PCA consumption (ml) |
1.5 (0–7) |
1.5 (0–8) |
1.5 (0–5) |
0.921 |
| Postoperative 2–24 h |
|
|
|
|
| Pain (VRS) |
27 (0–100) |
26 (0–85) |
26 (0–70) |
0.792 |
| PCA consumption (ml) |
11 (0–46) |
12 (20–75) |
13 (0–78) |
0.541 |
| Postoperative 24–48 h |
|
|
|
|
| Pain (VRS) |
17 (0–80) |
15 (0–60) |
18(0–70) |
0.589 |
| PCA consumption (ml) |
16 (1–95) |
26 (0.2-100) |
22 (0–88) |
0.345 |
| Advervse events |
|
|
|
|
| Drowsiness |
4 (10) |
5 (11) |
2 (5) |
0.528 |
| Dizziness |
7 (17) |
14 (32) |
6 (14) |
0.101 |
| Itching |
1 (2) |
1 (2) |
0 (0) |
0.604 |
| Others | 1 (2) | 0 (0) | 0 (0) | 0.347 |
Group A; ondansetron 4 mg group. Group B; ondansetron 8 mg group. Group C; ramosetron 0.3 mg group. Values are expressed as median (range) or number of the patients (%).